Back to top
more

Regulus Therapeutics (RGLS)

(Real Time Quote from BATS)

$2.49 USD

2.49
57,475

+0.07 (2.89%)

Updated Apr 29, 2024 11:36 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for RGLS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Regulus Therapeutics Inc. [RGLS]

Reports for Purchase

Showing records 101 - 120 ( 270 total )

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 101

12/20/2017

Daily Note

Pages: 5

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 102

12/20/2017

Daily Note

Pages: 5

Corporate Update and 2018 Outlook

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 103

12/11/2017

Daily Note

Pages: 7

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 104

12/11/2017

Company Report

Pages: 6

Cash Runway Covers Key Milestones over the Next 12 Months

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 105

08/07/2017

Company Report

Pages: 6

Q2 Financials and Outlook

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 106

07/28/2017

Industry Report

Pages: 4

The Week Ahead in Life Sciences: Upcoming Events for the Week of July 31

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 107

07/27/2017

Daily Note

Pages: 10

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 108

07/26/2017

Company Report

Pages: 6

Financing Provides Runway Through 2018 and Initial Alport Syndrome Results

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 109

06/13/2017

Daily Note

Pages: 5

Cleaning House Improves Focus, Financials, and Potential for Success.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 110

06/01/2017

Industry Report

Pages: 50

June and Full Year 2017 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 111

05/04/2017

Company Report

Pages: 7

Q1 Financials: Despite Management Shake-Up and 30% Reduction-in-Force, Pipeline On-Track for Material Catalysts; Reiterate OUTPERFORM and $6 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 112

05/02/2017

Daily Note

Pages: 46

May and Full Year 2017 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 113

04/28/2017

Daily Note

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of May 1

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 114

04/07/2017

Industry Report

Pages: 5

The Week Ahead in Life Sciences Upcoming Events for the Week of April 10.

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 115

04/04/2017

Daily Note

Pages: 46

April and Full Year 2017 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 116

03/29/2017

Daily Note

Pages: 6

Corporate Update: Pipeline Focus in 2017 on RG-012 for Alport Syndrome; Reiterate OUTPERFORM and $6 Price Target

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 117

03/29/2017

Daily Note

Pages: 6

Corporate Update: Pipeline Focus in 2017 on RG-012 for Alport Syndrome; Reiterate OUTPERFORM and $6 Price Target

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 118

03/08/2017

Daily Note

Pages: 42

March and Full Year 2017 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 100.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 119

03/06/2017

Company Report

Pages: 7

Q4/FY16; Early Proof-of-Mechanism for RG-012 for Rare Alport Syndrome Could Be Achieved Before Year-End

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Regulus Therapeutics Inc.

Industry: Medical - Drugs

Record: 120

02/10/2017

Daily Note

Pages: 5

The Week Ahead in Life Sciences: Upcoming Events for the Week of Feb 13

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party